GOVERNANCE

BOARD OF DIRECTORS

The Liver Foundation is governed by a Board of Directors, who ensure we maintain the highest level of ethics, compliance and governance. They generously donate their time, energy and professional expertise to support our mission, ‘to raise awareness and fund critical research into the prevention, detection and diagnosis, treatment, and cure of liver disease’.

Lynne Pezzullo.png

Dr Lynne Pezzullo - Chair

BEc (Hons 1), PhD


Elected to the Board as Chair in February 2022, Dr Lynne Pezzullo has an extensive career as a health economist who led the Health Economics and Social Policy team for Access Economics from 2001-2010 and, from 2011-2020, for Deloitte Australia and Deloitte Asia Pacific. Prior to this Dr Pezzullo worked as an international economist in the Commonwealth Treasury, Department of Defence, and Department of Foreign Affairs and Trade. Dr Pezzullo has published multiple reports and publications on a range of health and social conditions including liver disease and liver cancer, and has an extensive network across the health sector and policy-makers. Having served on some 20 boards, Executives and Advisory Groups over nearly 30 years, Dr Pezzullo is passionate to call upon her depth of experience and business acumen to lead the Foundation through a new phase of growth. 

Associate Professor Paul Clark
MBBS (Hons 1), MPH&TM, PhD, FRACP, FAChAM


Dr Paul Clark is the Director of the Alcohol and Drug Assessment Unit, and Senior Staff Specialist, Department of Gastroenterology at the Princess Alexandra Hospital, Brisbane. He is Clinical Lead, Hepatology at the Mater Hospital Brisbane.  He has provided specialist outreach services at Inala Indigenous Health Centre (CRE) and Central Queensland. His specialist training was completed in Brisbane and Duke University Medical Centre, North Carolina. He is an Associate Professor with the School of Medicine, University of Queensland. In addition to clinical and research interests in liver disease, addiction and their interaction, he has been involved developing innovative service models to address social determinants in health.  

John Dewar - Treasurer

B Com, CA, CTA, GAICD
 

John is qualified Chartered Accountant and a Graduate of the Australian Institute of Company Directors with sound governance experience obtained through his role as an Executive Director of Moore Australia and through Advisory Board & Non-Executive Director roles with various privately held businesses and not-for-profit bodies.

He has substantial professional experience providing commercial, financial analysis, financial reporting and taxation advice to privately held businesses and not-for-profit bodies.

John has core professional focus on the healthcare industry with a client base which includes device developers, device wholesalers, digital health providers, practices (allied health, dental & medical) and practitioners (general & specialist).

Professor Winita Hardikar

MBBS, FRACP, PhD, FAASLD, AM

Professor Winita Hardikar is Head of the Liver and Intestinal transplant program at the Royal Children's Hospital Melbourne , and a former director of the Department of Gastroenterology. She completed her medical training and a PHD at Melbourne University, and post graduate research at Yale University.

She has over 30 years experience in managing children with liver and bowel disorders and extensive research publications including an eponymous disease - Hardikar syndrome. She has received numerous awards including a Fulbright scholarship, Inaugural fellow of the American Assocation for the Study of Liver and in 2019 was awarded an AM (Member in the General Division of the Order of Australia) for her significant service to medicine, particularly to paediatric liver disease and transplantation. 

Professor Gary Jeffrey

MB BS, MD, FRACP, FRCP

Professor Gary Jeffrey is Winthrop Professor of Medicine at the University of Western Australia, Medical Director of the West Australian Liver Transplantation Service at Sir Charles Gairdner Hospital and was Chairman of the Liver Foundation of Western Australia.

He and co-investigators were awarded the 2006 WA Inventor of the year award for creating the ‘Hepascore’ which is a serum model of liver fibrosis. This is now used worldwide including in the United States, France and Australia. In addition to his clinical and teaching roles, his research interests are diverse and include the role of iron in preservation injury in the isolated donor liver, mechanisms of HCV viral resistance, clinical studies in liver fibrosis, liver transplantation and HCC.

Prof Grant Ramm 2 2022.png

Professor Grant Ramm
BSc, BSC(Hons), PhD, FAASLD

Professor Grant Ramm is the Deputy Director of QIMR Berghofer Medical Research Institute. He is also head of the Hepatic Fibrosis Research Laboratory and a Senior Principal Research Fellow at QIMR Berghofer.

His research at QIMR Berghofer has included investigation into the molecular, cellular and histopathological events involved in initiating hepatic fibrosis (liver scarring) in chronic liver disease associated with both hereditary haemochromatosis in adults and Cystic Fibrosis in children. Mechanistic evaluation of these cellular events will aid in identifying patients at risk of serious liver disease complications (including cirrhosis and liver cancer) and lead to the development of new biomarkers as well as novel therapeutic interventions to treat chronic liver disease.

Copy of Copy of Untitled (7).png

Mr David Smith
MBA (MIT Sloan Fellow), BBS, GAICD

Appointed to the Liver Foundation Board in December 2021, Mr David Smith has had over 30 years executive management and board director experience in financial services (banking, insurance, superannuation and investment management) across Australia and New Zealand. During this time, Mr Smith was a Director of Insurance Council of NZ from 2001-2006, serving as President from 2004-2006 and is a past Director of the Insurance Council of Australia 2007-2011. 

Mr Smith is presently Executive Director and Co-founder of EQUIP Corporate Advisory P/L and is also an active director in the not-for-profit sector having been the past Chair of the Children's Cancer Institute (Medical Research) 2011-2016. Mr Smith has recently been appointed as a Director for an aged care and home provider, KOPWA Ltd (2022) and, since 2019, has been an external member and Chair of the YWCA's Finance, Audit and Risk Committee.

Mr Edward Smith

Edward Smith is an experienced Philanthropic Fundraiser who has worked in Leadership roles across Public Health and Higher Education. Edward is a Non-Executive Director with a demonstrated history of working in the management consulting industry. Skilled in Business Planning, International Business, Event Management, International Relations, and Corporate Communications.

Associate Professor Simone Strasser
MBBS (Hons), MD, FRACP, FAASLD

 

Associate Prof Strasser is a Senior Staff Specialist in the AW Morrow Gastroenterology and Liver Centre, and the Australian National Liver Transplant Unit at Royal Prince Alfred Hospital and the University of Sydney. She has a major clinical and research interest in primary liver cancer, viral hepatitis, non-alcoholic fatty liver disease, advanced liver disease, and liver transplantation.

Associate Prof Strasser is Director of Hepatology Clinical Trials at RPAH, and is site principal investigator on multiple clinical trials of new therapies for patients with liver disease and liver cancer. She is a regular speaker in national and local educational programmes and sits on multiple educational, advisory, editorial and administrative boards and committees in Australia and internationally and is past President of the Gastroenterological Society of Australia (GESA).  

CHIEF EXECUTIVE OFFICER

Sally Castle (1).png

Sally Castle
BBus

 

Sally Castle is an internationally-recognised strategist delivering growth in revenue, reach and impact for values-based organisations, balancing commercial imperatives with social impact goals. Sally has over 20 years’ experience working in the health sector across medical research institutes, health peak bodies and private sector organisations.

SCIENTIFIC COMMITTEE

Prof Gary Jeffrey

Prof Luc Delriviere

Prof Leon Adams
Dr Wendy Cheng

 Dr Michaela Lucas